Skip to content

13F-HR filed by Commodore Capital LP

Commodore Capital LP filed this 13F-HR for the quarter ended 2021-06-30, filed 2021-08-16, with 29 holding rows worth $290,313,000.

Accession
0001831942-21-000005
Filed
2021-08-16
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q2 2021

A holdings report, 29 entries on the cover page, a total value of $290,313,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $290,313,000 with VALUE read as thousands by filing date, 13F file number 028-20976. A later restatement replaced it, so the quarter does not use it. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
ACLARIS THERAPEUTICS INC COM00461U105Stock1,668,987$29,307,000thousands by filing date
SATSUMA PHARMACEUTICALS INC80405P107COM3,096,729$21,832,000thousands by filing date
CELCUITY INC15102K100COM870,967$20,903,000thousands by filing date
C4 THERAPEUTICS INC12529R107COM STK481,094$18,205,000thousands by filing date
CYMABAY THERAPEUTICS INC23257D103COM3,529,465$15,388,000thousands by filing date
CONSTELLATION PHARMACEUTICALS INC.210373106Common Stock440,869$14,901,000thousands by filing date
CYTOKINETICS INC23282W605COM NEW704,317$13,938,000thousands by filing date
KURA ONCOLOGY INC COM50127T109Stock621,493$12,958,000thousands by filing date
COGENT BIOSCIENCES INC19240Q201COM1,367,582$11,091,000thousands by filing date
IVERIC BIO INC46583P102COM1,748,241$11,031,000thousands by filing date
CELLDEX THERAPEUTICS INC NEW15117B202COM NEW323,437$10,816,000thousands by filing date
MACROGENICS INC556099109COM393,850$10,579,000thousands by filing date
VISTAGEN THERAPEUTICS INC92840H202COM3,331,315$10,494,000thousands by filing date
PROTAGONIST THERAPEUTICS74366E102COM210,600$9,452,000thousands by filing date
ESSA PHARMA INC29668H708COM NEW281,911$8,054,000thousands by filing date
KRONOS BIO INC50107A104COM298,839$7,157,000thousands by filing date
GENOCEA BIOSCIENCES INC372427401COMMON STOCK2,929,447$6,855,000thousands by filing date
VIRIDIAN THERAPEUTICS INC92790C104COM366,414$6,701,000thousands by filing date
MEREO BIOPHARMA GROUP PLC589492107CMN2,059,729$6,529,000thousands by filing date
DYNE THERAPEUTICS INC COM26818M108Stock305,125$6,420,000thousands by filing date
XENON PHARMACEUTICALS INC COM98420N105Stock326,336$6,076,000thousands by filing date
Mersana Therapeutics Inc59045L106Common Stock429,228$5,829,000thousands by filing date
KALVISTA PHARMACEUTICALS INC483497103COM226,671$5,431,000thousands by filing date
PMV PHARMACEUTICALS INC69353Y103COM125,000$4,270,000thousands by filing date
INVENTIVA SA46124U107ADS262,658$3,581,000thousands by filing date
SERES THERAPEUTICS INC81750R102COM145,453$3,469,000thousands by filing date
CATABASIS PHARMACEUTICALS IN14875P206COM NEW1,617,000$3,412,000thousands by filing date
ARS PHARMACEUTICALS INC82835W108COM97,143$3,001,000thousands by filing date
BCLS ACQUISITION CORPG0904B105CMN250,000$2,633,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001831942-21-000005this filing2021-08-16acceptance time not in the bulk data set
13F-HR/A 0001831942-21-000007 base2021-10-14acceptance time not in the bulk data set